drugset / Trial / NCT00065767
Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease
Phase 2/3
Completed
20 enrolled
University of Wisconsin, Madison
National Institute on Aging (NIA) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.
Timeline
- Start
- 2001-09
- Primary completion
- 2005-03
- Completion
- 2005-03
Publications
- Background Birge SJ, McEwen BS, Wise PM. Effects of estrogen deficiency on brain function. Implications for the treatment of postmenopausal women. Postgrad Med. 2001 Mar;Spec No:11-6.
- Background Zec RF, Trivedi MA. The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev. 2002 Jun;12(2):65-109. doi: 10.1023/a:1016880127635.
- Background Yaffe K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? Ann N Y Acad Sci. 2001 Dec;949:215-22. doi: 10.1111/j.1749-6632.2001.tb04024.x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raloxifene | Other / unclassified | — | — |